#67856 RCAS1 (D8K2E) Mouse mAb
|ヒトのRCAS1 タンパク質のGly147 周辺領域 (合成ペプチド)|
ホモロジー (相同性) 検索をご希望の場合 >>>
Western blot analysis of extracts from MCF7 and T47D cells using RCAS1 (D8K2E) Mouse mAb.
Receptor binding cancer antigen expressed on SiSo cells (RCAS1) is also known as estrogen receptor-binding fragment-associated gene 9 (EBAG9). Originally identified as an estrogen-inducible gene (1), RCAS1 was recently found to play a novel role in the adaptive immune response by negatively regulating the cytolytic activity of cytotoxic T lymphocytes (CTLs) (2). RCAS1 is conserved in phylogeny and is ubiquitously expressed in most human tissues and cells (3,4). There is evidence that tissue expression of RCAS1 is increased in a variety of malignancies, including cancers of the gastrointestinal tract, liver, lung, breast, ovary, endometrium, and cervix. Research studies have shown that levels of RCAS1 tissue expression are negatively correlated with the prognosis of patients harboring the aforementioned malignancies (4). It is also noteworthy that research studies have detected elevated levels of RCAS1 in the sera of cancer patients (4). Initial studies indicated that RCAS1 was secreted from cancer cells and functioned as a ligand for a putative receptor expressed on NK cells, as well as T and B lymphocytes, inducing their apoptosis, which enabled cancer cells to evade immune surveillance (5,6). Subsequent studies have identified RCAS1 as a type III transmembrane Golgi protein with the ability to regulate vesicle formation, secretion, and protein glycosylation (2,7-9). Indeed, it has been shown that RCAS1 overexpression negatively regulates the cytolytic function of CTLs by negatively regulating protein trafficking from the trans-Golgi to secretory lysosomes (2). Furthermore, RCAS1 overexpression delays vesicle transport from the ER to Golgi and causes components of the ER quality control and glycosylation machinery to mislocalize. As a consequence, RCAS1 induces the deposition of tumor-associated glycan antigens on the cell surface, which are thought to contribute to tumor pathogenesis through the mediation of adhesion, invasion, and metastasis (8,9).
- Watanabe, T. et al. (1998) Mol Cell Biol 18, 442-9.
- Rüder, C. et al. (2009) J Clin Invest 119, 2184-203.
- Tsuchiya, F. et al. (2001) Biochem Biophys Res Commun 284, 2-10.
- Giaginis, C. et al. (2009) Histol Histopathol 24, 761-76.
- Matsushima, T. et al. (2001) Blood 98, 313-21.
- Nakashima, M. et al. (1999) Nat Med 5, 938-42.
- Reimer, T.A. et al. (2005) BMC Cancer 5, 47.
- Wolf, J. et al. (2010) FASEB J 24, 4000-19.
- Engelsberg, A. et al. (2003) J Biol Chem 278, 22998-3007.
DRAQ5 is a registered trademark of Biostatus Limited.
Tween is a registered trademark of ICI Americas, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
DyLight is a trademark of Thermo Fisher Scientific, Inc. and its subsidiaries.